Abstract
Study Objectives Narcolepsy type 1(NT1) is associated with loss of functioning hypocretin-producing neurons and an increase in histaminergic neuron numbers in the hypothalamus. These cell groups have largely overlapping projections to other brain regions, and may be associated with distributed patterns of secondary affection of sub-cortical and cortical gray matter. We performed a case-control comparison of MRI-based global and sub-cortical volume and cortical thickness in NT1 patients compared with healthy controls.
Methods We processed T1-weighted brain MRI data from 54 NT1 patients (51 with confirmed hypocretin-deficiency; 39 females, mean age 21.8 ± 11.0 years) and 114 healthy controls (77 females, mean age 23.2 ± 9.0 years) using FreeSurfer. Group differences among three global and 10 sub-cortical volume measures and 34 cortical thickness measures for bilateral brain regions were tested using general linear models with permutation testing. We corrected for multiple testing with the Benjamini-Hochberg procedure with the false discovery rate at 5%.
Results NT1 patients had significantly thinner brain cortex bilaterally in the temporal poles (Cohen’s d=0.68, p=0.00080), entorhinal cortex (d=0.60, p=0.0018) and superior temporal gyrus (d=0.60, p=0.0020) compared to healthy controls. The analysis revealed no significant group differences for sub-cortical volumes.
Conclusions NT1 patients have significantly thinner cortex in temporal brain regions compared to controls. We speculate that this effect can be partly attributed to the hypothalamic neuronal change in NT1, including loss of function of the widely projecting hypocretin-producing neurons and secondary effects of the abnormal sleep-wake pattern in NT1.
Statement of Significance Narcolepsy type 1 (NT1) patients have loss/dysfunction of hypocretin-producing neurons and increased histaminergic neurons number – cell groups which project widely to other brain regions. It is therefore plausible that other brain regions may be affected by the hypothalamic changes in NT1 patients. Compared to healthy controls, we show that NT1 patients have thinner cortex bilaterally in the entorhinal cortex, temporal poles and superior temporal gyrus (STG). STG play a role in hallucinations and entorhinal cortex and temporal poles in memory functions. Thinner cortex in these regions have been implicated in diseases sharing common features with NT1, like schizophrenia and obstructive sleep apnea. Further studies are needed to establish the clinical relevance and investigate possible causal effects using a longitudinal design.
Competing Interest Statement
H.T.J reports no competing interests. D.A. reports no competing interests. I.A. received speakers honorariumfrom Lundbeck. O.A.A. is a consultant for HealthLytix and has received speakers honorarium from Lundbeck and Sunovion. A.S. reports no competing interests. P.M.T. reports no competing interests. L.T.W reports no competing interests. S.K.H have been lecturing about narcolepsy for UCB Pharma AOP- Orphan Jazz-Pharmaceuticals Lundbeck AS - honorarium have been paid to Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom). S.K.H. has received honorarium for being an expert consultant for the Norwegian state regarding narcolepsy and Pandemrix.
Funding Statement
S. K. H was partially funded by research support from the Norwegian Ministry of Health and Care Services. H.T.J was during data collection fully funded by the Norwegian Ministry of Health and Care Services and during data analyses by the South-Eastern Norway Regional Health Authorities(2019032). D. A was supported by the South-Eastern Norway Regional Health Authorities (2019107, 2020086). The European Union's Horizon 2020 Research and Innovation program (ERC StG, Grant # 802998), the Research Council of Norway (223273, 249795, 300767) and the South-Eastern Norway Regional Health Authority (2019101) was also part of funding this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Norwegian regional committees for medical and health research ethics gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Due to ethical restrictions the data are not publicly available as it could compromise the privacy of the participants, as NT1 is a rare disorder and Norway has a relatively small population.
